Ocugen (NASDAQ: OCGN) is one of 29 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it contrast to its peers? We will compare Ocugen to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.
This is a summary of recent ratings and price targets for Ocugen and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 5.27%. Given Ocugen’s peers higher possible upside, analysts plainly believe Ocugen has less favorable growth aspects than its peers.
Risk & Volatility
Ocugen has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s peers have a beta of 1.13, meaning that their average share price is 13% more volatile than the S&P 500.
This table compares Ocugen and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
56.3% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 19.7% of Ocugen shares are owned by company insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Ocugen and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocugen Competitors||$1.39 billion||$142.47 million||18.30|
Ocugen’s peers have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.